Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Efforts Mount to Assure Quality of Emerging Pharma Technologies

This article was originally published in The Gold Sheet

Executive Summary

The regulatory challenges of emerging technologies are triggering an evolution in CMC review and GMP compliance approaches as regulatory agencies, drug manufacturers and standard-setting organizations strive to adapt 20th century concepts to 21st century science. FDA unveils an initiative to close ‘regulatory science’ gaps, while EMA drafts a road map for adapting its regulatory framework to novel scientific approaches. PQRI considers opportunities to contribute its scientific expertise at the government/industry nexus. The CMC Strategy Forum explores new approaches for antibody-drug conjugates. FDA launches nanotechnology initiative; CDER’s concerns about nanoparticles shared. FDA approves first ‘biopharm’ product, prepares for wave of applications. Manufacturing quality issues with transgenic bioreactors explored in context of GTC’s goat farm. How milking animals compares to milking CHO cells. On biosimilars, U.S. legislation stalls while the EU forges ahead with reviewing applications – and Japan declares a preference for ‘bio-betters.’ Meanwhile, the science for supporting bio-comparison remains lost in the folds of higher order structure. All could be clarified by NIST’s ambitious reference standard proposal.

You may also be interested in...



FDA Panel Can't Decide Whether Agency Should Issue Nanotechnology Guidance

Do nanotechnology-derived drugs merit their own GMPs? That remains an open question, say FDA advisors, unsure whether nanoguidance is warranted.

First Biosimilar Reviews Raise Questions About the Differences

DRUGS WON'T BE QUITE THE SAME in a biosimilar world, but does it really matter? Without better analytical technology, only clinical trials and post-marketing surveillance will tell. Global regulators are beginning to decide which differences they will allow, and on what basis. Recent approvals in India and China draw criticism at WCBP 2008 from Genentech official who explores uncertainties about growth hormones, other recombinants. The EU's new biosimilars framework and first approvals and denials are explained. Meanwhile, follow-on biologics regulation is planned by the World Health Organization, Japan and the U.S.

FDA Should Look Through IIRIS To Improve Science, Panel Says; Funding Is Worry

Increasing developments in emerging sciences, such as personalized medicine, could reach roadblocks at FDA where limited resources for specialized personnel and advanced equipment may inhibit research, a report from FDA's Science Board's Subcommittee on Science and Technology shows

Related Content

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel